DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mycobutin (Rifabutin) - Published Studies

 
 



Mycobutin Related Published Studies

Well-designed clinical trials related to Mycobutin (Rifabutin)

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. [2011.09]

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection. [2007.07.25]

Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. [2007.06]

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. [2006.07.15]

Well-designed clinical trials possibly related to Mycobutin (Rifabutin)

Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. [2011.01.15]

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. [2010.02]

Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. [2009.11]

Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. [2007.04.15]

Other research related to Mycobutin (Rifabutin)

Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. [2014]

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. [2013]

[Three cases of uveitis induced by mycobacteriosis therapy using rifabutin]. [2011.07]

Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. [2011.06]

Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. [2011.02]

[Susceptibility to rifabutin and novel fluoroquinolones in Mycobacterium avium complex isolates from patients with sputum culture-positive pulmonary disease who are undergoing standard chemotherapy]. [2010.11]

Decreased plasma efavirenz concentrations in a patient receiving rifabutin. [2010.10.01]

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. [2010.10]

[A new anti-mycobacterial agent, rifabutin]. [2010.10]

[Rifabutin-associated hypopyon uveitis in patient with acquired immunodeficiency syndrome] [2010.08]

[Rifabutin-associated hypopyon uveitis in patient with acquired immunodeficiency syndrome]. [2010.08]

Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease. [2010.06]

Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. [2010.05]

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. [2010]

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. [2009.12]

Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. [2009.11.01]

Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy. [2009.06]

Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. [2009.05.15]

Rifabutin corneal deposits in a patient with acquired immunodeficiency syndrome: in vivo confocal microscopy investigation. [2009.05]

Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. [2009.01]

Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. [2009]

Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. [2008.09]

Concomitant use of voriconazole and rifabutin in a patient with multiple infections. [2008.08]

Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. [2008.05.07]

[Rifabutin-associated with bilateral uveitis in an HIV negative patient] [2008.05]

[Rifabutin-associated with bilateral uveitis in an HIV negative patient] [2008.05]

One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. [2008.02]

Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. [2008.02]

Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. [2008.01.28]

Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. [2008.01]

Pharmacokinetic Interaction between Fosamprenavir/Ritonavir and Rifabutin in Healthy Subjects. [2007.12.03]

The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. [2007.12]

Rifabutin for treating pulmonary tuberculosis. [2007.10.17]

Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. [2007.06]

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. [2007.03]

Rifabutin-induced hypopyon uveitis in patients with acquired immunodeficiency syndrome infected with Mycobacterium avium complex. [2007.03]

Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice. [2007.03]

Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. [2007.01]

Toxic uveitis caused by pharmacodynamic interactions of Rifabutin and protease inhibitors: a case report. [2007]

Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. [2006.11.15]

[A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis] [2006.08]

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. [2006.02.15]

Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. [2005.12]

Rifabutin-associated uveitis in a child. [2005.11]

In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. [2005.09]

[Use of rifabutin in cases of toxicity to rifampicin] [2005.09]

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. [2005.07.01]

Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency. [2005.06.15]

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. [2005.05.15]

Corneal endothelial deposits associated with rifabutin use. [2005.04]

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. [2005.01.01]

Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. [2005.01]

Other possibly related research studies

Human immunodeficiency virus-positive patient with bilateral corneal endothelial deposits. [2006.10]

Bartonella quintana coinfection with Mycobacterium avium complex and CMV in an AIDS patient: case presentation. [2006.05.29]

Identification of new biomarkers for clinical trials of Hsp90 inhibitors. [2006.05]

First case of an oculofacial lesion due to Mycobacterium haemophilum infection in an immunocompetent child. [2006.06]

Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. [2006.05]

Hsp90 inhibitors in the clinic. [2006]

Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. [2005.04]

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. [2006.05]

Nontuberculous mycobacterial adenitis: effectiveness of chemotherapy following incomplete excision. [2006.02]

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. [2006.04.15]

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. [2005.10]

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. [2006.02.01]

Heat shock proteins and acute leukemias. [2005.06]

Eradication of Helicobacter pylori: recent advances in treatment. [2005.08]

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. [2005.06.20]

The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. [2005.06.01]

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. [2005.05.01]

Mycobacterium simiae: a previously undescribed pathogen in peritoneal dialysis peritonitis. [2005.05]

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. [2005.03.20]

Treatment of H. pylori infection: a review. [2005]

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. [2005.02.20]

Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. [2005.02]

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. [2005.03]

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. [2005.03]

Antiretroviral therapy in AIDS patients with tuberculosis. [2006.07]

[Atypical tuberculous osteomyelitis of the humeral shaft caused by Mycobacterium avium] [2006.08.05]

Effective regimens for the treatment of Helicobacter pylori infection. [2006.09]

Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. [2006.08]

'Rescue' therapies for the management of Helicobacter pylori infection. [2006]

Gateways to clinical trials. [2006.03]

Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. [2006.03]

Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. [2006.03]

A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia. [2006.02]

Advances in the diagnosis and treatment of tuberculosis. [2006]

Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. [2005.11.15]

Helicobacter pylori "rescue" therapy after failure of two eradication treatments. [2005.10]

[Treatment of Helicobacter pylori infection] [2005.09]

[Pulmonary infection due to Mycobacterium malmoense] [2005.04]

The role of ultrasound and echo-color Doppler in the diagnosis and follow-up of tuberculosis of the transplanted kidney. [2005.03]

[Drug induced uveitis] [2005.03]

Tipranavir: a novel second-generation nonpeptidic protease inhibitor. [2005.02]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017